RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway

Abstract

The activation of oncogenes and the inactivation of tumor suppressor genes by mutations or chronic hepatitis virus infections play key roles in the pathogenesis of hepatocellular carcinoma (HCC). Here we report that RN181, a really interesting new gene finger domain-containing protein, was down-regulated in highly malignant cell lines and in tumor cells of 139 HCC clinical samples in comparison with adjacent normal liver tissues. The expression of RN181 was strongly associated with the pathological grade of HCC. Alterations of the expression of RN181 by retrovirus-transduced up-regulation and short hairpin RNA-mediated down-regulation demonstrated the function of RN181 as a tumor suppressor because it decreased the proliferation and colony formation of HCC cells in vitro and inhibited tumor growth in vivo by suppressing cell proliferation and enhancing cell apoptosis in xenografted tumors. Proteomic analyses showed that RN181 regulates the expression of many proteins that are important in many cellular processes. Statistical analyses identified 33 proteins with consistent changes (!2-fold) in RN181-transformed cells. Ten of these proteins were up-regulated by RN181, and 23 were down-regulated. Representative proteins were validated by western blotting. Interaction network investigations revealed that 20 RN181-regulated proteins could integrate several key biological processes such as survival, metabolism, and mitogen-activated protein kinase (MAPK) pathways. Remarkably, 11 of the 33 proteins are associated with MAPK signaling in one or more ways. RN181 suppressed the tyrosine phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in cell lines and in tumor cells of xenografts and HCC clinical samples, and removing the suppression increased tumor growth. Conclusion: We have shown that RN181 suppresses the tumorigenesis of HCC through the inhibition of ERK/MAPK signaling in the liver. Our results provide new insights into the pathogenesis of HCC and may help with the development of novel therapeutic strategies. (HEPATOLOGY

Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling

“…ERK inhibitor is suggested as a potential anti-HCC agent (37)(38)(39). Sorafenib is the first targeted therapy drug that has demonstrated an improved overall survival benefit in patients with advanced HCC (40)(41)(42). Sorafenib can inhibit tumor cell proliferation in vitro by targeting the Raf/MEK/ ERK signaling pathway at the level of Raf kinase (43) and by targeting angiogenesis (44).…”

Tspan5 is an independent favourable prognostic factor and suppresses tumour growth in gastric cancer

“…IHC staining was done with the IHC kit as described previously [40]. Briefly, the TMAs were roasted for 3 h at 65°C, deparaffinized and rehydrated through dimethylbenzene and graded alcohols, and then rinsed in tap water for few seconds.…”

“…The final expression scores for statistical analysis were the product of the score of intensity and that of extent. The expression level of Tspan5 was considered high if the final score was ≥4 or low if the final score was <4 [40]. …”

The emerging role of astrocyte-elevated gene-1 in hepatocellular carcinoma (Review)

“…Aberrant activation of the MAPK pathway also plays a critical role in the development and progression of HCC (65,66). Analysis of signal transduction pathways revealed activation of ERK42/44 and p38 MAPK in Hep-AEG-1 clones compared to control Hep-pc-4 clones.…”